vic3308

º²É­ÖÆÒ© º²É­ÖÆÒ©

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾ ¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • vic3308¥Y
ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
ÐÂÎÅÐû²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅÐû²¼
2024 WCLCÔ¤¸æ | º²É­ÖÆÒ©¶àÏîÁ¢ÒìÑо¿ÁÁÏà¹ú¼ÊѧÊõÊ¢»á
Ðû²¼ÈÕÆÚ£º2024/08/23
×ÖºÅ

2024ÄêÌìÏ·ΰ©´ó»á£¨WCLC£©½«ÓÚÍâµØÊ±¼ä9ÔÂ7ÈÕÖÁ10ÈÕÔÚÃÀ¹úÊ¥µØÑǸçÕÙ¿ª¡£¡£¡£¡£¡£¡£¡£ÔÚ´ó»áÐû²¼µÄ¡°×îÐÂÍ»ÆÆÕªÒª(Late Breaking Abstract £¬£¬ £¬£¬£¬ £¬LBA)¡±Ãûµ¥ÖÐ £¬£¬ £¬£¬£¬ £¬º²É­ÖÆÒ©Ô­ÑÐÁ¢ÒìÒ©°¢ÃÀÌæÄá¼°±¸ÊܹØ×¢µÄ¹ÜÏß²úÆ·HS-20093ÒÀ¸½ÓÅÒìµÄÑо¿Ð§¹û˫˫ÈëÑ¡£¡£¡£¡£¡£¡£¡£»£»£»£» £»£»°¢ÃÀÌæÄáÉÐÓÐ12ƪÁ¢ÒìЧ¹ûÈëÑ¡±¾½ì´ó»á £¬£¬ £¬£¬£¬ £¬ÄÚÈݺ­¸Çи¨Öú¡¢¸¨Öú¡¢ÍŽữÁÆ¡¢ÍŽá·ÅÁÆ¡¢ÄÔ×ªÒÆµÈÁìÓò¡£¡£¡£¡£¡£¡£¡£



Part 1£º×îÐÂÍ»ÆÆÕªÒª£¨LBA£©




¡¾1.1¡¿ Aumolertinib Maintenance after Chemoradiotherapy in stage ¢ó Non-Small-Cell Lung Cancer: Interim Results of the phase ¢ó study (POLESTAR)

°¢ÃÀÌæÄáÓÃÓÚ·Å»¯Áƺó¢óÆÚ·ÇСϸ°û·Î°©µÄά³ÖÖÎÁÆ£º¢óÆÚÑо¿£¨POLESTAR£©µÄÖÐÆÚЧ¹û

×÷ÕߣºÓÚ½ðÃ÷¡¢ÃÏÏ鿝£¨É½¶«µÚÒ»Ò½¿Æ´óѧÁ¥ÊôÖ×ÁöÒ½Ôº£©

¡¾1.2¡¿ Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase ¢ñ Study (ARTEMIS-001)

Ò»Ïî¶àÖÐÐÄ¡¢¢ñÆÚÑо¿£¨ARTEMIS-O01£©ÖÐ HS-20093 ÖÎÁÆÆÕ±éÆÚСϸ°û·Î°©µÄÁÆÐ§ºÍÇå¾²ÐÔ

×÷ÕߣºÍõ½à£¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£© 


Part 2£ºÃÔÄã¿ÚÍ·±¨¸æ




¡¾2.1¡¿ Aumolertinib as adjuvant therapy in resectable ¢ñ-¢ó EGFR-mutant NSCLC : also effective in patients with high-risk relapse factors

°¢ÃÀÌæÄá×÷Ϊ¿ÉÇгý¢ñ-¢óÆÚEGFRÍ»±äNSCLC µÄ¸¨ÖúÖÎÁÆ£º¶Ô¾ßÓи´·¢¸ßΣÒòËØ»¼ÕßÒ²ÓÐÓÃ

×÷ÕߣºÒ¦½¡£¡£¡£¡£¡£¡£¡£¨¼ªÁÖÊ¡ÈËÃñÒ½Ôº£©


Part 3£ºÑо¿Éè¼Æ




¡¾3.1¡¿ MRD guiding treatment after Aumolertinib induction therapy for EGFRm+ stage ¢ó NSCLC in the MDT diagnostic model (APPROACH)

MDTÕïÁÆÄ£Ê½ÏÂEGFRÍ»±äÑôÐÔ²»¿ÉÇгý¢óÆÚ·ÇСϸ°û·Î°©¾­°¢ÃÀÌæÄáÓÕµ¼ÖÎÁƺóMRD¶¯Ì¬¼à²âÖ¸µ¼ÖÎÁƾöÒéµÄÓÐÓÃÐÔºÍÇå¾²ÐÔÑо¿£ºÒ»Ï·ÅÐÔ¡¢¶àÖÐÐÄ¡¢¢óÆÚÁÙ´²Ñо¿

×÷ÕߣºÖÜÇå¡¢ÎâÒ»Áú£¨¹ã¶«Ê¡ÈËÃñÒ½Ôº£©

¡¾Öйúר³¡ÌÖÂÛ±Ú±¨¡¿


¡¾3.2¡¿ Efficacy and safety of Aumolertinib with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC: a phase ¢ò study

°¢ÃÀÌæÄáÍŽá·ÅÁÆÖÎÁƲ»¿ÉÇоÖÍíÆÚµÄEGFRÍ»±äNSCLCµÄÁÆÐ§ºÍÇå¾²ÐÔ:Ò»Ïî¢òÆÚÑо¿

×÷ÕߣºÃÏÏ齿£¨É½¶«Ê¡Ö×ÁöÒ½Ôº£©



Part 4£ºÑо¿Êý¾Ý




¡¾4.1¡¿ Aumolertinib as neoadjuvant therapy for EGFRm+ NSCLC: a subcohort analysis of PURPOSE trial data updated

°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äNSCLC»¼ÕߣºPURPOSEÊÔÑéµÄÐÐÁÐÆÊÎö

×÷Õߣº·½ÎÄÌΣ¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©


¡¾4.2¡¿ Aumolertinib in treatment-na?ve EGFR-mutant NSCLC patients with brain metastases: efficacy and safety data from the ARTISTRY

°¢ÃÀÌæÄáÖÎÁƳõÕï·ÇСϸ°û·Î°©£¨NSCLC£©°éÄÔ×ªÒÆµÄÓÐÓÃÐÔÓëÇå¾²ÐÔ£ºARTISTRYÑо¿ÐÐÁÐ1

×÷ÕߣºÕÅÏþ¾ê¡¢Íõ»Û¾ê£¨ºÓÄÏÊ¡Ö×ÁöÒ½Ôº£©


¡¾4.3¡¿ Aumolertinib with chemotherapy as first-line treatment in patients with EGFR-mutated advanced NSCLC: a real-world study

°¢ÃÀÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC»¼ÕߣºÒ»ÏîÕæÊµÌìÏÂÑо¿

×÷ÕߣºÐíÓÈÎï¡¢¹ùÈË»¨£¨½­ËÕÊ¡ÈËÃñÒ½Ôº£©


¡¾4.4¡¿ Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage ¢ñ NSCLC with multiple high-risk factors

°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±ä°é¶àÖØ¸ßΣÒòËØµÄ¢ñÆÚNSCLC

×÷ÕߣºÎâÆë·É£¨Î÷°²½»´óÒ»¸½Ôº£©


¡¾4.5¡¿ Safety and efficacy of cranial radiotherapy in combination with Aumolertinib in EGFR-mutant NSCLC patients with brain metastases

EGFRÍ»±ä·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°¢ÃÀÌæÄáÍŽᾫ׼·ÅÁƵÄÁÆÐ§ºÍÇå¾²ÐÔ

×÷Õߣº±Ï骣¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©


¡¾4.6¡¿ Adjuvant Aumolertinib in resected stage I EGFR-mutated NSCLC: prospectively evaluating efficacy in residual GGN lesions

°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äIÆÚ·Î°©ÇгýÊõºó²ÐÁô·ÎÄ¥²£Á§½á½Ú

×÷Õߣº»Æ³ç±ê£¨Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº£©


¡¾4.7¡¿ Adjuvant Aumolertinib in patients with completely resected, stage ¢ñA2-¢óA Non-Small-Cell Lung Cancer with uncommon EGFR mutations

°¢ÃÀÌæÄḨÖúÖÎÁÆ¢ñA2-¢óAÆÚÓÐÊýEGFRÍ»±äNSCLC»¼Õß

×÷Õߣººú¼á£¨Õã½­´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½Ôº£©


¡¾4.8¡¿ Efficacy and safety of Aumolertinib in stage ¢ñB-¢óA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status

°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄ¢ñB-¢óAÆÚNSCLC»¼ÕßµÄÁÆÐ§ºÍÇå¾²ÐÔÒÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿

×÷ÕߣºÑîʤÀû£¨·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£©


Part 5£º²¡ÀýϵÁÐ




¡¾5.1¡¿ High-dose Aumolertinib combined intrathecal chemotherapy for the treatment of EGFR-mutated NSCLC with leptomeningeal metastasis

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆ

×÷ÕߣºÍõΰ£¨ÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£©


¹ØÓÚº²É­ÖÆÒ©

º²É­ÖÆÒ©ÊÇÖйúÁìÏȵÄÁ¢ÒìÇý¶¯ÐÍÖÆÒ©ÆóÒµ £¬£¬ £¬£¬£¬ £¬ÏÂÊôºÀÉ­Ò©Òµ¡¢³£Öݺã°îÒ©Òµ¡¢º²É­ÉúÎïÒ½Ò©µÈ×Ó¹«Ë¾ £¬£¬ £¬£¬£¬ £¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹Ñ¬È¾¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò £¬£¬ £¬£¬£¬ £¬ÖÂÁ¦ÓÚͨ¹ýÒ»Á¬Á¢ÒìÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ £¬£¬ £¬£¬£¬ £¬¹«Ë¾ÒÑÉÏÊÐ7¿îÁ¢ÒìÒ© £¬£¬ £¬£¬£¬ £¬Á¢ÒìÒ©ÓªÊÕÕ¼±ÈÒÑÍ»ÆÆÖÁ67.9%¡£¡£¡£¡£¡£¡£¡£¹«Ë¾Ò»Á¬¶àÄêλ¾ÓÈ«ÇòÖÆÒ©ÆóÒµ°ÙÇ¿¡¢ÖйúÒ½Ò©Ñз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿ £¬£¬ £¬£¬£¬ £¬Êǹú¼ÒÖØµã¸ßÐÂÊÖÒÕÆóÒµ¡¢¹ú¼ÒÊÖÒÕÁ¢ÒìÊ÷Ä£ÆóÒµ¡£¡£¡£¡£¡£¡£¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¡£¡£¡£¡£¡£¡£¸ü¶àÐÅÏ¢Çë»á¼û£º/¡£¡£¡£¡£¡£¡£¡£


  Ç°Õ°ÐÔ˵Ã÷

±¾ÎÄÖ¼ÔÚÌṩÓйء°º²É­ÖÆÒ©¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢ £¬£¬ £¬£¬£¬ £¬²»×é³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£¡£¡£¡£¡£¡£¡£

±¾ÎÄËùÐû²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üÀ¨Ä³Ð©Ç°Õ°ÐÔ±íÊö £¬£¬ £¬£¬£¬ £¬ÀýÈçÉæ¼°ÓªÒµºÍ²úÆ·Ô¶¾° £¬£¬ £¬£¬£¬ £¬»ò¹«Ë¾ÍýÏë¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°Õ½ÂÔ¡£¡£¡£¡£¡£¡£¡£ÕâЩ±íÊöÊǽ¨ÉèÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÕ¹Íû £¬£¬ £¬£¬£¬ £¬²¢·ÇÊǶÔδÀ´Éú³¤µÄ°ü¹Ü £¬£¬ £¬£¬£¬ £¬ÒòÆäÐÔ×ÓʹȻ¾ùÊÜÏà¹ØÎ£º¦ºÍ²»È·¶¨ÒòËØÓ°Ïì £¬£¬ £¬£¬£¬ £¬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ £¬£¬ £¬£¬£¬ £¬Í¶×ÊÕß¾ÙÐÐͶ×ʾöÒéʱӦÉóÉ÷ʹÓᣡ£¡£¡£¡£¡£¡£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÐÅÍС±¡°Õ¹Íû¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï¾ÙÐбíÊöʱ £¬£¬ £¬£¬£¬ £¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö £¬£¬ £¬£¬£¬ £¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¡£¡£¡£¡£¡£¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö £¬£¬ £¬£¬£¬ £¬¹«Ë¾¡¢¹«Ë¾¶­Ê¡¢¹ÍÔ±¡¢ÊðÀí¸Å²»¼ç¸ºÒòÈκÎǰհÐÔ±íÊö²»¿ÉʵÏÖ»òÄð³É²»×¼È·¶øÒýÖµÄÈκÎÔðÈΡ£¡£¡£¡£¡£¡£¡£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟåÐû²¼Ö®ÈÕ £¬£¬ £¬£¬£¬ £¬ÎÞÂÛÊÇ·ñ·ºÆðÐÂ×ÊÁÏ¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐÎ £¬£¬ £¬£¬£¬ £¬³ý·ÇÖ´·¨ÒªÇó £¬£¬ £¬£¬£¬ £¬¹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£Í¶×ÊÕßÒ˲ÎÕÕº²É­ÖÆÒ©£¨03692.HK£©Í¨¸æ¼°²Æ±¨ £¬£¬ £¬£¬£¬ £¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿